Human antibodies targeting TDP-43 for the treatment of central nervous system diseases.

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

11241.1;9 PFLS-LS

Projekttitel

Human antibodies targeting TDP-43 for the treatment of central nervous system diseases.

Projekttitel Englisch

Human antibodies targeting TDP-43 for the treatment of central nervous system diseases.

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Human antibodies targeting TDP-43 for the treatment of central nervous system diseases.
Abstract (Englisch)	The intended project is aimed at the development of human monoclonal antibodies for immunotherapy against aggregated TDP-43, a novel target for the treatment and prevention of amyotrophic lateral sclerosis. Possible further indications include a wide spectrum of neurodegenerative diseases such as frontotemporal dementia and Alzheimer¿s disease. Combining Neurimmune¿s RTMTM human antibody technology and the University of Zurich¿s expertise in neurodegenerative disease research and clinical development, the program results will be instrumental for the anticipated commercialization of therapeutic TDP-43 antibodies.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Human antibodies targeting TDP-43 for the treatment of central nervous system diseases.

Abstract
(Englisch)

The intended project is aimed at the development of human monoclonal antibodies for immunotherapy against aggregated TDP-43, a novel target for the treatment and prevention of amyotrophic lateral sclerosis. Possible further indications include a wide spectrum of neurodegenerative diseases such as frontotemporal dementia and Alzheimer¿s disease. Combining Neurimmune¿s RTMTM human antibody technology and the University of Zurich¿s expertise in neurodegenerative disease research and clinical development, the program results will be instrumental for the anticipated commercialization of therapeutic TDP-43 antibodies.